Table 2 Ten years fracture outcomes in all participants.

From: FGF21 is a novel biomarker to predict fragility fractures in patients with type 2 diabetes mellitus

Type of fractures

All

(n = 371)

T2D

(n = 203)

Non-T2D

(n = 168)

P-value

Vertebral fractures*, n (%)

6 (1.6)

4 (2.0)

2 (1.2)

0.693

Hip fractures, n (%)

5 (1.4)

4 (2.0)

1 (0.6)

0.383

Major fractures†, n (%)

24 (6.5)

20 (9.9)

4 (2.4)

0.004

Any fractures#, n (%)

27 (7.3)

21 (10.3)

6 (3.6)

0.012

  1. *Vertebral fractures included either clinical or morphological vertebral fracture.
  2. †Major fractures included clinical or morphological fragility fractures in any area except the skull, hand, foot and ankle.
  3. #Any fractures included fragility fractures in any area.
Back to article page